ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study to Evaluate the Efficacy and Safety of Dermalax(Deep) in Correction of Nasolabial Folds

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02179619
Recruitment Status : Completed
First Posted : July 2, 2014
Last Update Posted : July 2, 2014
Sponsor:
Information provided by (Responsible Party):
Across Co.,Ltd.

Brief Summary:
The study is to verify that Dermalax (Deep) is not inferior to the reference device, Restylane®, in terms of efficacy and safety in the correction of nasolabial folds. Subjects who voluntarily signed the informed consent and are judged to be eligible for this study will be intradermally injected both of study device and comparator device. Subjects will be randomized to receive injection of study device and comparator device on their each nasolabial fold. Efficacy is evaluated based on the change in Wrinkle Severity Rating Scale (WSRS) from baseline. Safety will be assessed based on 24 weeks follow up visits and subject diary which will be given to subjects during the first 2 weeks after the injection. Any uncomfortable things and adverse events will be investigated from subject diary and follow up visits.

Condition or disease Intervention/treatment Phase
Correction of Nasolabial Folds Device: Dermalax(Deep) Device: Restylane Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Multi-center, Patient & Evaluator-blind, Matched Pairs, Active-controlled Design Clinical Study to Evaluate the Efficacy and Safety of Injection With Dermalax(Deep) as Compared to Restylane® in Correction of Nasolabial Fold
Study Start Date : December 2012
Actual Primary Completion Date : January 2014
Actual Study Completion Date : February 2014

Arm Intervention/treatment
Experimental: Dermalax(Deep)
subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
Device: Dermalax(Deep)
Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period

Device: Restylane
Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period

Active Comparator: Restylane
Subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
Device: Dermalax(Deep)
Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period

Device: Restylane
Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period




Primary Outcome Measures :
  1. Wrinkle Severity Rating Scale(WSRS) evaluation [ Time Frame: at week 24 ]
    Wrinkle Severity Rating Scale(WSRS) evaluation at week 24


Secondary Outcome Measures :
  1. The mean of the WSRS scores from both the Dermalax (Deep) group and the Restylane® group [ Time Frame: at week 8~ 48 ]
    Wrinkle severity system scale(WSRS) evaluation at week8, week 16, week 36, week 48 by independent evaluator

  2. The mean of the WSRS scores from both the Dermalax (Deep) group and the Restylane® group [ Time Frame: at week 8~ 48 ]
    Wrinkle severity system scale(WSRS) evaluation at week8, week 16, week 24, week 36, week 48 by investigator

  3. The mean of the Global Aesthetic Improvement Scale(GAIS) scores from both the Dermalax (Deep) group and the Restylane® group [ Time Frame: at week 8~48 ]
    Global Aesthetic Improvement Scale(GAIS) evaluation at week8, week 16, week 36, week 48 by investigator

  4. Mean of the Global Aesthetic Improvement Scale(GAIS) scores from both the Dermalax (Deep) group and the Restylane® group [ Time Frame: at week 8~48 ]
    Global Aesthetic Improvement Scale(GAIS) scores evaluation at week 8, 16, 24, 36, 48 by subjects

  5. The proportion of subjects whose WSRS scores decreased at least 1 level [ Time Frame: at week 0~48 ]
    the proportion of subjects whose Wrinkle severity system scale(WSRS) scores decreased at least 1 level at week 24, 36, 48 by independent evaluator.

  6. The proportion of subjects whose WSRS scores decreased at least 1 level [ Time Frame: at week 0~48 ]
    the proportion of subjects whose Wrinkle severity system scale(WSRS) scores decreased at least 1 level at week 24, 36, 48 by investigator



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female subjects no younger than 30 and no more than 65 years of age.
  2. Subjects who scored 3 or 4 on the Wrinkle Severity Rating Scale (WSRS) and want to improve the appearance of their nasolabial folds (the subject does not need to have the same score on both sides.*)

    *The scores need not to be same on both sides, but the two nasolabial folds should have symmetry in the range of 3-4.

  3. Subjects who have symmetric nasolabial folds.
  4. Subjects who agreed to discontinue the use of any dermatological procedure or therapy, including facial wrinkle reduction procedures.
  5. Subjects with the ability to understand and follow the instructions and who are committed to availability for the entire study period.
  6. Subjects who have voluntarily decided to participate in this study and who have signed the informed consent form.

Exclusion Criteria:

  1. Subjects who show hypersensitive skin reaction to the investigational devices, confirmed by the intradermal reaction test performed at screening.
  2. Subjects who received an antithrombotic agent within 2 weeks prior to screening (with the exception of low dose Aspirin 100 mg, maximum of 300 mg/day) or NSAIDs or Vitamin E within 1 week.
  3. Subjects with a liver problem and/or blood coagulation defect or subjects who require the administration of an antithrombotic agent during the clinical trial period (with the exception of low dose Aspirin 100 mg, maximum of 300 mg/day).
  4. Subjects who have used a local ointment on their faces (medication such as steroid or retinoid are included and cosmetic products are excluded from this criterion) within 4 weeks prior to screening or subjects who are planning on using such an ointment during the clinical trial period.
  5. Subjects who have received treatment for wrinkles or acne within 24 weeks prior to screening.
  6. Subjects who have received facial (chemical) peels and/or skin rejuvenation procedures or plastic surgeries, including the injection of the Botulinum toxin, within 24 weeks prior to screening.
  7. Subjects who have a permanent skin expander such as soft form or silicon implanted in the face.
  8. Subjects who have scars on the face requiring a medical treatment but who have not received any treatment for more than a year or subjects who have scars or wounds on which the test investigational devices will be applied.
  9. Subjects with skin disease or wound infection on the face.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02179619


Locations
Korea, Republic of
Chung-ang University Hospital
Seoul, Korea, Republic of
Eulji General Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Across Co.,Ltd.
Investigators
Principal Investigator: Beom Joon Kim, PhD Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Principal Investigator: Jong Hoon Lee, PhD Eulji General Hospital

Responsible Party: Across Co.,Ltd.
ClinicalTrials.gov Identifier: NCT02179619     History of Changes
Other Study ID Numbers: HG-HADNSF-12103
First Posted: July 2, 2014    Key Record Dates
Last Update Posted: July 2, 2014
Last Verified: June 2014

Additional relevant MeSH terms:
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents